Last reviewed · How we verify
SPL84
At a glance
| Generic name | SPL84 |
|---|---|
| Sponsor | SpliSense Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPL84 CI brief — competitive landscape report
- SPL84 updates RSS · CI watch RSS
- SpliSense Ltd. portfolio CI